Empiric antibiotic treatment of serious bacterial infections in children has been complicated within the last two decades by evolving resistance to traditional antibiotics such as aminopenicillins and cephalosporins. The availability of fifth-generation cephalosporins such as ceftaroline offers an opportunity to simplify such empiric treatment. The increasing proportion of clindamycin resistant Staphylococcus aureus (S. aureus) strains and the need to continue to provide coverage for methicillin resistant S. aureus (MRSA) plus highly penicillin resistant Streptococcus pneumoniae aid despite the benefits of 13-valent conjugate pneumococcal vaccine (PCV 13) have required clinicians to use combinations of potent antibiotics sometimes with the potential for notable adverse effects. Combinations such as vancomycin plus a third-generation cephalosporin or even a carbapenem frequently choices for children admitted to intensive care units with serious bacterial infections. Because pneumococcus and Staphylococcus aureus are frequent pathogens in these serious bacterial infections, it is important to confirm ceftaroline's activity against a broad array of isolates obtained from clinical samples among children. We use standard CLSI recommended methods to compare activity of ceftaroline to 11 traditional antibiotics used to treat pediatric infections, when tested in vitro against clinical isolates obtained at a Midwest United States Children's Hospital from 2007 two 2014.